BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gubanski M, Johnsson A, Fernebro E, Kadar L, Karlberg I, Flygare P, Berglund A, Glimelius B, Lind PA; Gastric Cancer Taxotere vs. Campto Trial (GATAC) Study Group. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer 2010;13:155-61. [PMID: 20820984 DOI: 10.1007/s10120-010-0553-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Kacprzak KM. Chemistry and Biology of Camptothecin and its Derivatives. In: Ramawat KG, Mérillon J, editors. Natural Products. Berlin: Springer Berlin Heidelberg; 2013. pp. 643-82. [DOI: 10.1007/978-3-642-22144-6_26] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
2 Ter Veer E, van Kleef JJ, Sprangers MAG, Haj Mohammad N, van Oijen MGH, van Laarhoven HWM. Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. Gastric Cancer 2018;21:183-95. [PMID: 29380191 DOI: 10.1007/s10120-018-0792-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
3 van Kleef JJ, ter Veer E, van den Boorn HG, Schokker S, Ngai LL, Prins MJ, Mohammad NH, van de Poll-franse LV, Zwinderman AH, van Oijen MGH, Sprangers MAG, van Laarhoven HWM. Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute 2019. [DOI: 10.1093/jnci/djz133] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
4 Zhang D, Wu JR, Duan XJ, Wang KH, Zhao Y, Ni MW, Liu SY, Zhang XM, Zhang B. A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer. Front Pharmacol 2019;10:717. [PMID: 31333452 DOI: 10.3389/fphar.2019.00717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Li Z, Chen J, Chan KW, Qiao L, Wong BC. A possible role of cIAP2 in Helicobacter pylori-associated gastric cancer. Cancer Letters 2011;313:192-200. [DOI: 10.1016/j.canlet.2011.09.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
6 Hultman B, Lundkvist J, Glimelius B, Nygren P, Mahteme H. Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer. Acta Oncol. 2012;51:112-121. [PMID: 22070666 DOI: 10.3109/0284186x.2011.594809] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
7 Sun J, Ren Z, Sun X, Hou H, Li K, Ge Q. Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis. Oncotarget. 2017;8:39673-39682. [PMID: 28562333 DOI: 10.18632/oncotarget.17784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs. 2011;71:1367-1384. [PMID: 21812503 DOI: 10.2165/11592530-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
9 Price TJ, Shapiro JD, Segelov E, Karapetis CS, Pavlakis N, Van Cutsem E, Shah MA, Kang YK, Tebbutt NC. Management of advanced gastric cancer. Expert Rev Gastroenterol Hepatol. 2012;6:199-208; quiz 209. [PMID: 22375525 DOI: 10.1586/egh.11.103] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
10 Kim R, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: Is there a standard approach? Crit Rev Oncol Hematol. 2013;88:416-426. [PMID: 23764501 DOI: 10.1016/j.critrevonc.2013.05.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
11 Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, Zureikat A, Holtzman M, Lee K, Ahrendt S. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol. 2014;21:1448-1455. [PMID: 24197761 DOI: 10.1245/s10434-013-3327-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
12 Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064. [PMID: 28850174 DOI: 10.1002/14651858.cd004064.pub4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 166] [Article Influence: 15.4] [Reference Citation Analysis]
13 Kulig J, Kołodziejczyk P, Kulig P, Legutko J. Targeted therapy for gastric cancer--current status. J Oncol Pharm Pract 2013;19:75-81. [PMID: 22711713 DOI: 10.1177/1078155212449030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
14 Petrioli R, Francini E, Roviello F, Marrelli D, Fiaschi AI, Laera L, Rossi G, Bianco V, Brozzetti S, Roviello G. Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. Cancer Chemother Pharmacol 2015;75:941-7. [DOI: 10.1007/s00280-015-2715-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
15 Janmaat VT, Steyerberg EW, van der Gaast A, Mathijssen RH, Bruno MJ, Peppelenbosch MP, Kuipers EJ, Spaander MC. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 2017;11:CD004063. [PMID: 29182797 DOI: 10.1002/14651858.cd004063.pub4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
16 Gubanski M, Glimelius B, Lind PA. Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). Med Oncol 2014;31:906. [PMID: 24627237 DOI: 10.1007/s12032-014-0906-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
17 Wei X, Juan ZX, Min FX, Nan C, Hua ZX, Qing FZ, Zheng L. Recombinant immunotoxin anti-c-Met/PE38KDEL inhibits proliferation and promotes apoptosis of gastric cancer cells. J Exp Clin Cancer Res 2011;30:67. [PMID: 21733192 DOI: 10.1186/1756-9966-30-67] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
18 Hultman B, Mahteme H, Sundbom M, Ljungman M, Larsson R, Nygren P. Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy. J Exp Clin Cancer Res. 2014;33:110. [PMID: 25528067 DOI: 10.1186/s13046-014-0110-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
19 Hultman B, Lind P, Glimelius B, Sundbom M, Nygren P, Haglund U, Mahteme H. Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy. Acta Oncol. 2013;52:824-830. [PMID: 22974074 DOI: 10.3109/0284186x.2012.702925] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
20 Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial. Medicine (Baltimore) 2016;95:e2565. [PMID: 26817912 DOI: 10.1097/MD.0000000000002565] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]